TOP-5 Analyst Price Targets on 07.10.25
Reading Time: 3 minutes
Cartesian Therapeutics [US8162123025] Wedbush starts coverage with "Outperform" and price target of $38 (162% upside potential) At the center of attention is Cartesian's innovative cell therapy platform based on mRNA, which significantly differs from traditional CAR-T therapies. Notably, this therapy does not require a conditioning pre-treatment, which increases safety and simplifies administration. The leading drug Descartes-08 targets the BCMA antigen and is currently being tested in a Phase 3 approval study for the treatment of Myasthenia...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
